Pharmaceutical company Insmed announced Tuesday it will halt development of a medication intended to treat a painful inflammatory skin disorder following unsuccessful clinical trial results.
The experimental treatment, known as brensocatib, failed to achieve its primary objective of reducing painful nodules in individuals suffering from hidradenitis suppurativa during mid-stage testing, according to company officials.
“While we are disappointed in the results, we hope that insights gained from this study will contribute to the broader scientific understanding of HS,” stated Martina Flammer, Insmed’s Chief Medical Officer.
Company representatives noted that the medication demonstrated acceptable safety profiles during testing, with no unexpected adverse reactions identified. The pharmaceutical firm intends to share the trial findings at an upcoming scientific conference.
This marks the second setback for brensocatib this year, as Insmed previously abandoned its development for treating chronic sinus conditions in December following another unsuccessful trial.
Despite these failures, brensocatib continues to maintain U.S. approval under the brand name Brinsupri for treating non-cystic fibrosis bronchiectasis, a persistent respiratory condition that causes permanent damage to lung airways.
